Introduction
anti-AChR
Myasthenia gravis (MG) is a rare, chronic, autoimmune condition that affects the neuromuscular junction [Approximately 85% of patients with gMG have autoantibodies directed against the acetylcholine receptor (AChR) [Traditional therapies for MG include oral cholinesterase inhibitors and long-term immune therapies, such as corticosteroids and non-steroidal immunosuppressants (including azathioprine, mycophenolate mofetil, cyclosporin, and tacrolimus) [We have previously reported data from the phase 3, randomized, placebo-controlled CHAMPION MG study showing that ravulizumab is well tolerated and improves clinical outcomes compared with placebo in patients with anti-AChR antibody-positive gMG [